Common diabetes drug may shield kidneys from chemo damage

NCT ID NCT07018622

Recruiting now Disease control Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for a few days around their chemo session. Researchers will measure kidney injury markers in urine to see if the drug offers protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a diabetes drug that helps protect kidneys)
What this could lead to: If it works, this could offer a simple way to protect kidneys during chemotherapy, reducing treatment delays and improving cancer outcomes.
What could go wrong: This is a small, early-phase trial (46 people) testing a biomarker, not a proven benefit. The drug may not reduce kidney injury or could cause side effects like dehydration or electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CISPLATIN NEPHROTOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cisplatin toxicity neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CISPLATIN NEPHROTOXICITY SOLID TUMORS

Contacts and locations

Locations

Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
RECRUITING

México, Tlalpan, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.